NEW YORK, NY / ACCESSWIRE / February 7, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies reports on recent activity in shares of Pulmatrix Inc. PULM. Pulmatrix Inc., a clinical stage biopharmaceutical company focused on treating lung diseases, disclosed the FDA's approval of its ARYMO product on January 9, 2017. Prior to this announcement, PULM reported earnings for the third quarter of 2016 on November 4, 2016. Revenues beat consensus expectations, though EPS fell short of estimates.
The full report addresses the tough questions and dynamics of the ARYMO FDA approval READ MORE
(Copy and paste to browser may be required to view the full report- http://bit.ly/2ljeVFr-PULM-Report)
Opioid use as a prescription pain killer has given birth to a market prone to addiction to the medicine. The reason is that opioids are a type of drug that include both heroin, an illegal drug, and legal pain relievers. According to the American Society of Addiction Medicine, drug overdose was the leading cause of accidental death in 2015 in the US with 55,403 deaths, of which over 20,000 related to prescription pain relievers. 2 million Americans suffered from substance use disorder involving prescription pain relievers.
Not only is current opioid addiction a problem, but, unfortunately, past and future growth potential remain enormous. The American Society of Addiction Medicine claims that in 2012, prescriptions of pain-relieving opioids amounted to 259 million, enough to provide every single American adult with his or her own bottle of pills. Furthermore, sales of prescription pain relievers increased four-fold from 1999 to 2010. Substance abuse rates increased six-fold from 1999 to 2009.
An in-depth look at Pulmatrix financial position and potential cash requirements READ MORE
(Copy and paste to browser may be required to view the full report- http://bit.ly/2ljeVFr-PULM-Report)
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Stuart Quint, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email between 09:30 EST to 16:00 EST from Monday through Friday at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
